1. |
|
2. Introduction to drugtargets and molecularpharmacology |
Pharmacology introduction, The nature of drug targets |
|
2. |
|
2. Introduction to drugtargets and molecularpharmacology |
Pharmacology introduction, The nature of drug targets |
|
3. |
|
3. Molecular cloning of drug targets |
The relevance of recombinant DNA technology to pharmacology/drug discovery |
|
4. |
|
Molecular cloning of drug targets, Agonist selectivity |
The cloning of drug targets |
|
5. |
|
Agonist selectivity, Affinity, Efficacy |
Agonist selectivity, Affinity, Efficacy |
|
6. |
|
Efficacy, Drugs with multiple efficacies, Quantifying agonist activity, Bi-Molecular Systems, What is drug antagonism |
Efficacy, Drugs with multiple efficacies, Quantifying agonist activity, Bi-Molecular Systems, What is drug antagonism |
|
7. |
|
What is drug antagonism, Antagonist potency, Mechanism of receptor antagonism, Competitive and non-competitive antagonism |
What is drug antagonism, Antagonist potency, Mechanism of receptor antagonism, Competitive and non-competitive antagonism |
|
8. |
|
Orthosteric antagonist,Competitive and non-competitive antagonism |
Orthosteric antagonist,Competitive and non-competitive antagonism |
|
9. |
|
Characteristic properites of allosteric molecules and how they interact with proteins |
1. Introduction 2. protein allosterism 3. types of allosteric modulators 4. Unique effects of allosteric modulators 5. Detecting allosterism 6. Summary |
|
10. |
|
Introduction to molecularpharmacology, G-protein coupled receptors |
G-protein coupled receptors, Ion channels |
|
11. |
|
Ion Channels, Nuclear receptors, Transporters |
Ion Channels, Nuclear receptors, Transporters |
|
12. |
|
Molecular Pharmacology |
GPCR |
|
13. |
|
Molecular Pharmacology |
GPCR |
|
14. |
|
Signal transduction pathway, Desensitization and down-regulation of GPCR signaling, Constitutive GPCR activity |
Signal transduction pathway, Desensitization and down-regulation of GPCR signaling, Constitutive GPCR activity |
|
15. |
|
Promiscuous G protein coupling, Agonist-directed signalling, Allosteric modulators of GPCR function, Pharmacological chaperones for GPCRs |
Promiscuous G protein coupling, Agonist-directed signalling, Allosteric modulators of GPCR function, Pharmacological chaperones for GPCRs |
|
|
|
Pharmacological chaperones for GPCRs, GPCR dimerization, GPCR splice variants |
Pharmacological chaperones for GPCRs, GPCR dimerization, GPCR splice variants |
|
|
|
GPCR dimerization |
Methods to study GPCR dimerzation, Homodimerization, Heterodimerization |
|
|
|
Class C GPCR |
Class C GPCR |
|
|
|
GPCR splice variants have an influence on GPCR pharmacology |
GPCR splice variants have an influence on GPCR pharmacology |
|
|
|
GPCR drug examples, Voltage-gated ion channels |
GPCR drug examples, Voltage-gated ion channels |
|
|
|
Voltage-gated ion channels |
Voltage-gated ion channels |
|
|
|
Voltage-gated ion channels, Ligand-gated ion channels |
Voltage-gated ion channels, Ligand-gated ion channels |
|
|
|
Ligand-gated ion channels |
Ligand-gated ion channels |
|